IL6 and autoimmune hepatitis: MRS also alleviated inflammation by reducing the elevated serum levels of interleukin-6 (IL-6), TNF-α, interleukin-1β (IL-1β) and interferon-γ (IFN-γ) and activated nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPK) both in concanavalin A–induced autoimmune hepatitis [16] and in carbon tetrachloride-induced liver injury [53].